Is CNTX or INO more profitable?

Context Therapeutics' return on equity of -82.06% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media prefer CNTX or INO?

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Inovio Pharmaceuticals and 3 mentions for Context Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.25 beat Context Therapeutics' score of -0.12 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer FHTX or CNTX?

In the previous week, Foghorn Therapeutics had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 6 mentions for Foghorn Therapeutics and 3 mentions for Context Therapeutics. Foghorn Therapeutics' average media sentiment score of -0.11 beat Context Therapeutics' score of -0.12 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CNTX or GNLX more profitable?

Context Therapeutics' return on equity of -82.06% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Genelux N/A -205.85% -138.79%

Does the media refer more to CNTX or GNLX?

In the previous week, Genelux had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Genelux and 3 mentions for Context Therapeutics. Genelux's average media sentiment score of 0.94 beat Context Therapeutics' score of -0.12 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COYA or CNTX?

In the previous week, Coya Therapeutics had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 6 mentions for Coya Therapeutics and 3 mentions for Context Therapeutics. Coya Therapeutics' average media sentiment score of 0.56 beat Context Therapeutics' score of -0.12 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CNTX or RANI more profitable?

Context Therapeutics' return on equity of -82.06% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Rani Therapeutics N/A -104.60% -65.17%

Does the media refer more to CNTX or RANI?

In the previous week, Context Therapeutics had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.89 beat Context Therapeutics' score of -0.12 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Context Therapeutics (CNTX) Competitors

$0.24 -0.02 (-5.91%)

Closing price 04:00 PM Eastern

Extended Trading

$0.26 +0.02 (+7.69%)

As of 07:54 PM Eastern

Compare

CNTX vs. INO, FHTX, GNLX, COYA, and RANI

Should you buy Context Therapeutics stock or one of its competitors? Context Therapeutics's main competitors and comparable companies include Inovio Pharmaceuticals (INO), Foghorn Therapeutics (FHTX), Genelux (GNLX), Coya Therapeutics (COYA), and Rani Therapeutics (RANI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Context Therapeutics compare to Inovio Pharmaceuticals?

Context Therapeutics (NASDAQ:CNTX) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Context Therapeutics has higher earnings, but lower revenue than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Inovio Pharmaceuticals	$60K	1,699.21	-$84.95M	-$0.91	N/A

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 4 mentions for Inovio Pharmaceuticals and 3 mentions for Context Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.25 beat Context Therapeutics' score of -0.12 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics' return on equity of -82.06% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Context Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Context Therapeutics currently has a consensus target price of $6.17, suggesting a potential upside of 2,312.62%. Inovio Pharmaceuticals has a consensus target price of $3.17, suggesting a potential upside of 221.16%. Given Context Therapeutics' higher possible upside, equities research analysts plainly believe Context Therapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Context Therapeutics beats Inovio Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Context Therapeutics compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Foghorn Therapeutics presently has a consensus price target of $6.14, indicating a potential upside of 232.05%. Context Therapeutics has a consensus price target of $6.17, indicating a potential upside of 2,312.62%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Context Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Context Therapeutics has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	3.55	-$74.28M	-$0.98	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Foghorn Therapeutics has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Foghorn Therapeutics had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 6 mentions for Foghorn Therapeutics and 3 mentions for Context Therapeutics. Foghorn Therapeutics' average media sentiment score of -0.11 beat Context Therapeutics' score of -0.12 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Context Therapeutics	N/A	-82.06%	-72.74%

Summary

Foghorn Therapeutics beats Context Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Genelux?

Context Therapeutics (NASDAQ:CNTX) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Context Therapeutics presently has a consensus target price of $6.17, indicating a potential upside of 2,312.62%. Genelux has a consensus target price of $18.00, indicating a potential upside of 675.86%. Given Context Therapeutics' higher possible upside, equities research analysts plainly believe Context Therapeutics is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Genelux has higher revenue and earnings than Context Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Genelux	$10K	10,495.68	-$32.15M	-$0.86	N/A

In the previous week, Genelux had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Genelux and 3 mentions for Context Therapeutics. Genelux's average media sentiment score of 0.94 beat Context Therapeutics' score of -0.12 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics' return on equity of -82.06% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Genelux	N/A	-205.85%	-138.79%

Context Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Genelux has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Summary

Genelux beats Context Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Coya Therapeutics has higher revenue and earnings than Context Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	12.33	-$21.23M	-$1.07	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

In the previous week, Coya Therapeutics had 3 more articles in the media than Context Therapeutics. MarketBeat recorded 6 mentions for Coya Therapeutics and 3 mentions for Context Therapeutics. Coya Therapeutics' average media sentiment score of 0.56 beat Context Therapeutics' score of -0.12 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Context Therapeutics	N/A	-82.06%	-72.74%

Coya Therapeutics presently has a consensus price target of $15.33, suggesting a potential upside of 266.83%. Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 2,312.62%. Given Context Therapeutics' higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Context Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Coya Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

Summary

Coya Therapeutics beats Context Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Rani Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Context Therapeutics' return on equity of -82.06% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Rani Therapeutics	N/A	-104.60%	-65.17%

Context Therapeutics has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Rani Therapeutics has higher revenue and earnings than Context Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Rani Therapeutics	$1.63M	57.32	-$29.67M	-$0.27	N/A

Context Therapeutics currently has a consensus target price of $6.17, indicating a potential upside of 2,312.62%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 1,205.58%. Given Context Therapeutics' higher possible upside, research analysts plainly believe Context Therapeutics is more favorable than Rani Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Context Therapeutics had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.89 beat Context Therapeutics' score of -0.12 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Rani Therapeutics beats Context Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.48M	$3.91B	$7.32B	$12.93B
Dividend Yield	N/A	3.65%	2.51%	22.94%
P/E Ratio	N/A	8.24	178.18	17.78
Price / Sales	N/A	1,162.36	563.81	80.29
Price / Cash	N/A	118.95	76.19	51.56
Price / Book	0.36	15.79	10.32	6.01
Net Income	-$36.12M	-$22.69M	$3.50B	$380.68M
7 Day Performance	-19.57%	-4.31%	-2.54%	-3.01%
1 Month Performance	-34.00%	-11.49%	-6.87%	-5.59%
1 Year Performance	-82.05%	4.54%	1.81%	-5.23%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	3.2049 of 5 stars	$0.24 -5.9%	$6.17 +2,464.1%	-81.5%	$23.48M	N/A	N/A	15	News Coverage Analyst Downgrade
INO Inovio Pharmaceuticals	2.4604 of 5 stars	$1.13 -2.2%	$3.17 +181.5%	-59.6%	$117.36M	$60K	N/A	112	Analyst Downgrade
FHTX Foghorn Therapeutics	2.2495 of 5 stars	$1.97 -1.8%	$6.67 +239.3%	-57.5%	$116.69M	$36.74M	N/A	106	Analyst Downgrade High Trading Volume
GNLX Genelux	2.582 of 5 stars	$2.54 -2.3%	$18.00 +608.7%	-56.1%	$114.91M	$10K	N/A	26	Analyst Downgrade Gap Up
COYA Coya Therapeutics	2.3142 of 5 stars	$4.88 +0.6%	$15.33 +214.2%	-41.9%	$114.02M	$7.95M	N/A	8	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. INO, FHTX, GNLX, COYA, and RANI

How does Context Therapeutics compare to Inovio Pharmaceuticals?

Summary

How does Context Therapeutics compare to Foghorn Therapeutics?

Summary

How does Context Therapeutics compare to Genelux?

Summary

How does Context Therapeutics compare to Coya Therapeutics?

Summary

How does Context Therapeutics compare to Rani Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. INO, FHTX, GNLX, COYA, and RANI

How does Context Therapeutics compare to Inovio Pharmaceuticals?

Which has stronger earnings & valuation, CNTX or INO?

Does the media prefer CNTX or INO?

Is CNTX or INO more profitable?

Do insiders & institutionals hold more shares of CNTX or INO?

Which has more volatility and risk, CNTX or INO?

Do analysts rate CNTX or INO?

Summary

How does Context Therapeutics compare to Foghorn Therapeutics?

Do analysts rate FHTX or CNTX?

Which has better earnings & valuation, FHTX or CNTX?

Which has more volatility & risk, FHTX or CNTX?

Do insiders and institutionals believe in FHTX or CNTX?

Does the media prefer FHTX or CNTX?

Is FHTX or CNTX more profitable?

Summary

How does Context Therapeutics compare to Genelux?

Do institutionals & insiders have more ownership in CNTX or GNLX?

Do analysts rate CNTX or GNLX?

Which has stronger earnings and valuation, CNTX or GNLX?

Does the media refer more to CNTX or GNLX?

Is CNTX or GNLX more profitable?

Which has more risk and volatility, CNTX or GNLX?

Summary

How does Context Therapeutics compare to Coya Therapeutics?

Which has preferable earnings & valuation, COYA or CNTX?

Does the media prefer COYA or CNTX?

Is COYA or CNTX more profitable?

Do analysts rate COYA or CNTX?

Do insiders & institutionals hold more shares of COYA or CNTX?

Which has more volatility and risk, COYA or CNTX?

Summary

How does Context Therapeutics compare to Rani Therapeutics?

Is CNTX or RANI more profitable?

Which has more risk & volatility, CNTX or RANI?

Which has higher valuation & earnings, CNTX or RANI?

Do analysts rate CNTX or RANI?

Does the media refer more to CNTX or RANI?

Do insiders and institutionals believe in CNTX or RANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools